Gilteritinib

Phase 3

Astellas Pharma (ALPMY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Advanced Solid Tumors

DSKYFDS1025

Phase 1

View Full Landscape

Drug Information

Target Indication

Advanced Solid Tumors

Clinical Trial

NCT02561455

Last updated: 12/31/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/24/2019

Xospata

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

micafungin (Mycamine)Phase 3

Fungemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts